“…Success was defined by eyes achieving ≥ 20% IOP reduction from baseline on the same or fewer medications without glaucoma-related secondary surgical intervention (SSI) or intention to be converted to another procedure. mITT, modified intent-to-treat; phaco, phacoemulsification with intraocular lens replacement studies with this device, including the US pivotal trial in refractory glaucoma [23], as well as independent, retrospective [14,17,18,[24][25][26] and prospective [12,13,15,16,19,[27][28][29] studies in glaucoma, showing effectiveness at 1 year. Among those, a prospective, open-label study of the implant used alone or in combination with cataract surgery (N = 149 eyes) [16] showed that the mean medicated IOP and mean number of medications decreased from 20.0 (7.1) mmHg and 1.9 (1.3) at baseline to 13.9 (4.3) mmHg (P < 0.01) and 0.5 (0.8) (P < 0.001) at 1 year, respectively.…”